Either ablation of the PIKFYVE gene in dendritic cells or apilimod inhibition of PIKFYVE restrained tumor growth, enhanced dendritic cell-dependent T-lymphocyte immunity, and potentiated the efficacy of the immune checkpoint blockade in tumor-bearing mouse models. Here, PIKFYVE is linked to neoplasm.